CTKB - Company ID 0001831915
Cytek Biosciences, Inc. trades as CTKB. In its fiscal 2025 annual report the company posted revenue of $201.49M, up 0.5% from the prior year and net income of -$66.54M. This page tracks Cytek Biosciences, Inc. through 432 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
With latest filings
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Over the last 5 fiscal years Cytek Biosciences, Inc.'s revenue grew from $710.00K to $201.49M, a compound annual growth rate of 209.5%. Net profit margin compressed from 2733.9% to -33.0% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Insider trade | 4 | 2026-05-20 |
| Insider trade | 4 | 2026-05-20 |
| Insider trade | 4 | 2026-05-20 |
| Insider trade | 4 | 2026-05-20 |
| Insider trade | 4 | 2026-05-20 |
| Insider trade | 4 | 2026-05-20 |
| Insider trade | 4 | 2026-05-20 |
| SCHEDULE 13G/A | - | 2026-05-18 |
The largest companies sharing Cytek Biosciences, Inc.'s SEC industry classification (laboratory analytical instruments).
Cytek Biosciences, Inc. reported revenue of $201.49M for fiscal year 2025, an increase of 0.5% year over year.
In its latest fiscal year Cytek Biosciences, Inc. reported a net loss of $66.54M.